TN2010000290A1 - Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives - Google Patents

Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Info

Publication number
TN2010000290A1
TN2010000290A1 TN2010000290A TN2010000290A TN2010000290A1 TN 2010000290 A1 TN2010000290 A1 TN 2010000290A1 TN 2010000290 A TN2010000290 A TN 2010000290A TN 2010000290 A TN2010000290 A TN 2010000290A TN 2010000290 A1 TN2010000290 A1 TN 2010000290A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical compositions
active ingredient
digestive enzymes
protein active
protects digestive
Prior art date
Application number
TN2010000290A
Other languages
English (en)
French (fr)
Inventor
Farid Bennis
Jean Jacques Serrano
Original Assignee
Farid Bennis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farid Bennis filed Critical Farid Bennis
Publication of TN2010000290A1 publication Critical patent/TN2010000290A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TN2010000290A 2007-12-19 2010-06-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives TN2010000290A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0759971A FR2925333B1 (fr) 2007-12-19 2007-12-19 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
PCT/FR2008/052357 WO2009083686A1 (fr) 2007-12-19 2008-12-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Publications (1)

Publication Number Publication Date
TN2010000290A1 true TN2010000290A1 (fr) 2011-11-11

Family

ID=39671377

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2010000290A TN2010000290A1 (fr) 2007-12-19 2010-06-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Country Status (19)

Country Link
US (1) US8309123B2 (cg-RX-API-DMAC10.html)
EP (1) EP2234598B1 (cg-RX-API-DMAC10.html)
JP (1) JP5676272B2 (cg-RX-API-DMAC10.html)
KR (2) KR20150132887A (cg-RX-API-DMAC10.html)
CN (1) CN101917967B (cg-RX-API-DMAC10.html)
AP (1) AP3573A (cg-RX-API-DMAC10.html)
AR (1) AR069847A1 (cg-RX-API-DMAC10.html)
AU (1) AU2008345474B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0821373B8 (cg-RX-API-DMAC10.html)
CA (1) CA2709899C (cg-RX-API-DMAC10.html)
EA (1) EA023107B1 (cg-RX-API-DMAC10.html)
ES (1) ES3055634T3 (cg-RX-API-DMAC10.html)
FR (1) FR2925333B1 (cg-RX-API-DMAC10.html)
IL (1) IL206364A (cg-RX-API-DMAC10.html)
MA (1) MA31927B1 (cg-RX-API-DMAC10.html)
MX (1) MX2010006927A (cg-RX-API-DMAC10.html)
TN (1) TN2010000290A1 (cg-RX-API-DMAC10.html)
TW (1) TWI461226B (cg-RX-API-DMAC10.html)
WO (1) WO2009083686A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
CA2947528C (en) 2014-05-01 2023-09-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
BR112017001968A2 (pt) 2014-07-30 2017-11-21 Sun Pharmaceutical Ind Ltd embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
EP3215128B1 (en) * 2014-11-04 2019-09-04 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
FR3120189B1 (fr) * 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE36225B1 (en) * 1971-01-28 1976-09-15 Nat Res Dev Improvements relating to insulin derivatives
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
EP0179904A1 (en) 1984-05-09 1986-05-07 Medaphore Inc. Oral insulin and a method of making the same
US4693433A (en) * 1986-06-06 1987-09-15 Merrill David Martin Unwind stand for web rolls
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
WO1996006632A1 (en) * 1994-09-01 1996-03-07 Allied Medical Research Associates Compositions and methods for delivery of polypeptides
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6531648B1 (en) * 1998-12-17 2003-03-11 Syngenta Participations Ag Grain processing method and transgenic plants useful therein
EP1031347B1 (en) * 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US6531112B2 (en) * 2000-05-15 2003-03-11 Delrx Pharmaceutical Corporation Formulations for administering calcitonin and processes for preparing the same
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
GB0119859D0 (en) * 2001-08-15 2001-10-10 Qinetiq Ltd Eye tracking system
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
WO2005113008A1 (en) * 2004-05-21 2005-12-01 Mediplex Corp. Delivery agents for enhancing mucosal absorption of therapeutic agents
CN101027318B (zh) * 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
PL1883394T3 (pl) 2005-05-23 2018-09-28 Sdg, Inc. Konstrukt lipidowy do dostarczania insuliny ssakowi
WO2007032018A1 (en) * 2005-09-15 2007-03-22 Council Of Scientific And Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES
US20070134332A1 (en) * 2005-11-21 2007-06-14 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin

Also Published As

Publication number Publication date
JP5676272B2 (ja) 2015-02-25
HK1146386A1 (en) 2011-06-03
EA023107B1 (ru) 2016-04-29
EP2234598C0 (fr) 2025-11-19
IL206364A (en) 2016-12-29
FR2925333A1 (fr) 2009-06-26
AU2008345474B2 (en) 2014-07-31
CN101917967B (zh) 2013-05-22
US8309123B2 (en) 2012-11-13
IL206364A0 (en) 2010-12-30
MX2010006927A (es) 2010-12-06
WO2009083686A1 (fr) 2009-07-09
BRPI0821373A2 (pt) 2015-06-16
EP2234598B1 (fr) 2025-11-19
US20090176691A1 (en) 2009-07-09
TW200940107A (en) 2009-10-01
BRPI0821373B8 (pt) 2021-05-25
AP2010005298A0 (en) 2010-06-30
EA201070746A1 (ru) 2011-02-28
WO2009083686A9 (fr) 2009-10-15
TWI461226B (zh) 2014-11-21
CA2709899C (fr) 2018-01-16
KR20150132887A (ko) 2015-11-26
KR20100095449A (ko) 2010-08-30
KR101592609B1 (ko) 2016-02-05
JP2011506587A (ja) 2011-03-03
AP3573A (en) 2016-02-08
CA2709899A1 (fr) 2009-07-09
AU2008345474A1 (en) 2009-07-09
BRPI0821373B1 (pt) 2020-04-22
EP2234598A1 (fr) 2010-10-06
ES3055634T3 (en) 2026-02-13
MA31927B1 (fr) 2010-12-01
CN101917967A (zh) 2010-12-15
FR2925333B1 (fr) 2012-04-13
AR069847A1 (es) 2010-02-24

Similar Documents

Publication Publication Date Title
MA31927B1 (fr) Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
Kim et al. Bacterial-derived exopolysaccharides enhance antifungal drug tolerance in a cross-kingdom oral biofilm
MA35904B1 (fr) Formulations stabilisées contenant des anticorps anti-ang2
FR2856594A1 (fr) Particules poreuses chargees en compose(s) actif(s) cosmetique(s) ou pharmaceutique(s)
TR200801337T1 (tr) Suda zayıf çözülebilen farmasötik ajanlar ve antimikrobiyal ajanlar içeren kompozisyonlar.
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
MA33592B1 (fr) Formulations pharmaceutiques hautement concentrées
MA31606B1 (fr) Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
EA200800064A1 (ru) Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
WO2008017867A3 (en) Antiretroviral solid oral composition with at least one water insoluble polymer
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
MA32168B1 (fr) Compositions tensioactives
CY1112917T1 (el) Υγρες στοματικες συνθεσεις
PL1962815T3 (pl) Zastosowanie błonotwórczych polimerów do pielęgnacji włosów z grupy poluretanów i zawierające te polimery preparaty i plastry farmaceutyczne
FR2858556B1 (fr) Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
FR2884252B1 (fr) Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
GB2443793B (en) Product, method of manufacture and use
AR037131A1 (es) Formulaciones de jarabe de ribavirina
EA200301046A1 (ru) Комбинация действующих веществ с биорегуляторными свойствами
EA200500958A1 (ru) Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения
WO2003000174A3 (en) Compositions and methods for intracellular delivery
WO2008035129A3 (en) The application of the oil fraction obtained from sour cherry (prunus cerasus) seed kernel
MA20150424A1 (fr) Compositions liquides orales pédiatriques contenant du nepadutant